Pharmaceutical manufacturers challenging Federal Anti-Kickback Statute
Pharmaceutical manufacturers are challenging breadth of Federal Anti-Kickback Statute AKS in federal court, arguing government is harming vulnerable patients it aims to serve by prohibiting cost-sharing subsidies for life-saving oncology drugs. Advisory Opinion No. 22-19 OIG.